Rentschler expands manufacturing capacity again, this time with stainless steel

By Zachary Brennan contact

- Last updated on GMT

Related tags: Stainless steel, Biotechnology

Rentschler expands manufacturing capacity with stainless steel
The Laupheim, Germany-based CMO (contract manufacturing organization) Rentschler Biotechnologie has invested €24m ($33m) to build a twin stainless steel bioreactor system. 

The two 3,000 L stainless steel bioreactors will mainly target market supply at the company’s site in Laupheim, Germany, and are expected to be operational in early 2017.

The company defended its investment in stainless steel, as opposed to single-use, by noting that manufacturing in stainless steel “is far from being outdated​,” especially for market supply and late clinical phases.

The twin-bioreactor system is designed for running two main bioreactors in parallel with one shared downstream processing unit to provide higher throughput while reducing labor costs. The system will integrate with the existing 3,000 L GMP line and will more than double the production capacities for cell culture-derived proteins at Rentschler.

What’s unique is that the twin system will allow the company to run cell culture processes in fed-batch mode with a high output in a single suite.

The expansion will strengthen our global competitiveness and increase our market awareness of being a CMO partner of first choice all the way down from early clinical trials up to approval and market supply with a wide range of manufacturing technologies to offer​,” said Frank Ternes, Chief Business Officer at Rentschler.

The expansion comes as the company doubled its capacity last month by adding a 2,000 L single-use bioreactor​ to its German facility, which it expects to go live in the first quarter of 2015.

In the last few years, Rentschler has been heavily investing in other single-use technologies, according to the company. 

Related topics: Processing equipment

Related news

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us